EuBiologics to Invest US$ 10M in US Joint Venture 'EuPOP Life Sciences'

EuBiologics has announced a strategic investment of approximately US$ 10 million (KRW 14.9 billion) to acquire additional shares in its US-based joint venture, EuPOP Life Sciences. With this investment, EuBiologics will expand its stake in EuPOP Life Sciences to 80%, securing greater corporate control and accelerating its global research and development initiatives.

 

​EuPOP Life Sciences is a joint venture established between EuBiologics and US-based Pop Biotechnologies. The entity develops next-generation vaccines by combining EuBiologics’ immune enhancement platform technology, 'EulMT', with Pop Biotechnologies’ antigen display platform, 'SNAP'.​

 

The joint venture’s current pipeline includes premium vaccine candidates such as 'EuRSV' (for respiratory syncytial virus) and 'EuHZV' (for shingles), both of which are currently in Phase 1 clinical trials in South Korea, alongside an ongoing program for an Alzheimer's disease (AD) vaccine.​

 

To learn more, please click here: https://www.biospectator.com/news/view/28233